Proteomics International Laboratories logo

Proteomics International Laboratories(ASX) PIQ

Market CapA$19.84MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)-47%
5 Year-86%
1 Year-67%
1 Month-14%
A$0.13
+4.17%
+0.01Today
Proteomics International Laboratories last closing stock price
MetricPriceDate
Last closeAUD 0.132026-10-09
Proteomics International Laboratories stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+4.17%AUD 0.122026-10-02
1 month-13.79%AUD 0.152026-09-09
3 month-39.02%AUD 0.212026-07-10
Year to date-80.92%AUD 0.662025-12-31
1 year-66.67%AUD 0.382025-10-09
3 year-86.84%AUD 0.952023-10-10
5 year-85.8%AUD 0.882021-10-08
Since inception-46.67%AUD 0.232015-04-16

Proteomics International Laboratories Financials at a Glance

Market Cap

A$19.84MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$1.24M

Net Income (TTM)

-A$16.67M

EPS (TTM)

-A$0.06

P/E Ratio

-1.90

Dividend

A$0.00

Beta (Volatility)

-0.05 (Low)

Price

A$0.13

Volume

128,239

Open

A$0.12

Previous Close

A$0.13

Daily Range

A$0.12 - A$0.13

52-Week Range

A$0.10 - A$0.86

Estimated Earnings Date

Feb 25, 2027

PIQ News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Proteomics International Laboratories

Proteomics International Laboratories Ltd is a medical technology company specializing in proteomics, focusing on innovative diagnostic solutions. The company operates in multiple regions, including Australia, New Zealand, the United States, Europe, India, and Southeast Asia.

Products and Services
  • PromarkerD: A blood test predicting diabetic kidney disease
  • PromarkerEndo: Diagnostic test for endometriosis, completed clinical validation
  • Analytical services: Specializing in biomarker discovery and pharmacokinetic testing
Growth Outlook
  • Expansion into new markets is underway, enhancing global reach
  • Development of multiple diagnostic tests is progressing, increasing product portfolio
  • Strategic collaborations with research institutions are strengthening innovation
Financial Highlights
  • Recent quarterly revenue of -79,425 AUD indicates ongoing challenges
  • Cash and cash equivalents at 3.5 million AUD, providing operational liquidity
  • Current ratio of 3.19 suggests strong short-term financial health
Proteomics International Laboratories Ltd is positioned in a growing sector with significant potential for innovation in medical diagnostics. The company’s focus on developing advanced tests for various diseases, including diabetic kidney disease and endometriosis, highlights its commitment to addressing critical health issues. Despite recent financial challenges, the strong current ratio indicates a solid foundation for navigating operational hurdles. The ongoing development of new products and strategic partnerships may provide avenues for future growth and market expansion. Investors may find the company's innovative approach and market potential noteworthy as it continues to evolve in the healthcare landscape.
AI Generated • Sep 27, 2026

Industry

Life Sciences Tools and Services

CEO

David N. Morris

Headquarters

Nedlands, WA 6009, AU

PIQ Financials

Key Financial Metrics (TTM)

Gross Margin

-3262.02%

Operating Margin

-4275.74%

Net Income Margin

-3078.86%

Return on Equity

-129.15%

Return on Capital

-193.68%

Return on Assets

-96.36%

Earnings Yield

-52.63%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$19.84MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

165.37M

Volume

128.24K

Avg. Volume

162.22K

Financials (TTM)

Gross Profit

-A$13.42M

Operating Income

-A$22.35M

EBITDA

-A$21.07M

Operating Cash Flow

-A$12.47M

Capital Expenditure

-A$2.04M

Free Cash Flow

-A$14.52M

Cash & ST Invst.

A$3.50M

Total Debt

A$331.13K

Proteomics International Laboratories Performance Analysis

Proteomics International Laboratories annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 730,340-51.0%
20242024-06-30AUD 892,14322.2%
20252025-06-30AUD 587,389-34.2%
20262026-06-30AUD 278,015-52.7%
Proteomics International Laboratories sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31-68.5%
Q42025-06-30-85.3%
Q22025-12-31190.6%
Q42026-06-30-122.2%
Proteomics International Laboratories annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -0.0512.5%
20242024-06-30AUD -0.05-4.3%
20252025-06-30AUD -0.0619.1%
20262026-06-30AUD -0.05-13.7%
Proteomics International Laboratories sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31-44.9%
Q42025-06-30-1.7%
Q22025-12-31-20.7%
Q42026-06-3041.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

-A$79.43K

-103.0%

Gross Profit

-A$4.07M

-362.2%

Gross Margin

51.19%

N/A

Market Cap

A$19.84MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$123.26K

N/A

Employees

161

N/A

Net Income

-A$2.53M

+3.5%

EBITDA

-A$4.89M

-104.2%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$3.50M

-47.3%

Total Debt

A$331.13K

+4.7%

Accounts Receivable

A$460.28K

+149.8%

Inventory

A$0.00

N/A

Long Term Debt

A$126.60K

-42.7%

Short Term Debt

A$204.54K

+114.5%

Return on Assets

-96.36%

N/A

Return on Invested Capital

-1.70%

N/A

Free Cash Flow

-A$4.87M

-13.8%

Operating Cash Flow

-A$4.92M

-15.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NOX.AXNoxopharm Limited
A$0.06-1.61%
NSB.AXNeuroScientific Biopharmaceuticals Limited
A$0.06+0.00%
RAD.AXRadiopharm Theranostics Limited
A$0.01+0.00%
CSX.AXCleanSpace Holdings Limited
A$0.42-16.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
VEEAVeea
$6.09+57.36%
TAT&T
$23.04-6.33%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$34.04+0.74%
SPCXSpace Exploration Technologies
$163.11+1.58%

Questions About PIQ

What is the current price of Proteomics International Laboratories?

Proteomics International Laboratories is trading at A$0.13 per share.

What is the 52-week range for Proteomics International Laboratories?

Over the past 52 weeks, Proteomics International Laboratories has traded between A$0.10 and A$0.86.

How much debt does Proteomics International Laboratories have?

As of the most recent reporting period, Proteomics International Laboratories reported total debt of A$331.13K.

How much cash does Proteomics International Laboratories have on hand?

Proteomics International Laboratories reported A$3.50M in cash and cash equivalents in its most recent financial results.

What is Proteomics International Laboratories’s dividend yield?

Proteomics International Laboratories does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.